Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads CT scans to spot pancreatic cancer faster

NCT ID NCT07439757

Diagnosis Sponsor: Changhai Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an artificial intelligence (AI) system that analyzes contrast-enhanced CT scans to help diagnose and manage pancreatic diseases. The AI will classify patients into three groups: needing immediate treatment, close monitoring, or routine follow-up. Researchers will compare the AI's recommendations to those of experienced doctors to see if it can improve accuracy and reduce unnecessary surgeries. The trial aims to enroll 2,000 participants with suspected pancreatic conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Artificial intelligence diagnostic system
What this could lead to
If successful, this AI could help doctors more accurately diagnose pancreatic diseases, reducing missed cancers and unnecessary surgeries.
What could go wrong
This is an early-stage study comparing AI to human experts, and the AI may not perform as well in real-world settings or with all patient types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study enrolls patients with clinically suspected pancreatic disease who have available contrast-enhanced CT scans and provide informed consent. Patients are excluded if they have a history of pancreatic surgery, contraindications to contrast media, suboptimal image quality, or other conditions deemed unsuitable by the investigator (e.g., pregnancy, cognitive impairment, or concurrent trial participation).

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinically suspected pancreatic disease. * Scheduled to undergo contrast-enhanced CT. * Signed informed consent form indicating agreement to participate. Exclusion Criteria: * History of pancreatic surgery. * Contraindications to contrast-enhanced CT, including known hypersensitivity to iodinated contrast media or severe renal/hepatic dysfunction. * Suboptimal image quality affecting diagnosis. * Concurrent participation in another interventional clinical trial. * Unsuitability for participation as determined by the investigator, including but not limited to: pregnancy or lactation, severe psychiatric disorders or cognitive impairment, significant comorbidities that may interfere with study results or patient safety.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pancreatitis (AP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute pancreatitis Adenoma, Islet Cell chronic pancreatitis cystic tumor of the pancreas malignant pancreatic neoplasm Pancreatic Intraductal Neoplasms pancreatic intraductal papillary-mucinous neoplasm pancreatic neoplasm pancreatic neuroendocrine tumor pancreatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pancreatitis (AP) Chronic pancreatitis Diagnose disease Ipmn, pancreatic Pancreatic cancer Pancreatic cystic lesions Pancreatic neuroendocrine tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Changhai Hospital

    RECRUITING

    Shanghai, 200433, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.